Alkermes (NASDAQ:ALKS) reported interim results from its ongoing long-term extension study of alixorexton in adults with narcolepsy type 1 and narcolepsy type 2, showing sustained improvements in wakefulness, sleepiness and patient-reported outcomes after 24 weeks.
Ionis Pharmaceuticals (NASDAQ:IONS) announced that the first participant has been dosed in the Phase 1-2 ASCEND study evaluating ION337, an investigational RNA-targeted medicine for children with Dravet syndrome, a rare neurological disorder.
Bristol Myers Squibb (NYSE:BMY) announced that the U.S. Food and Drug Administration accepted its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone, known as MeziKd, for patients with relapsed or refractory multiple myeloma.
Q32 Bio (NASDAQ:QTTB) reported positive 36-week topline results from Part B of the Phase 2a SIGNAL-AA trial evaluating bempikibart in 33 patients with severe or very severe alopecia areata.
ANI Pharmaceuticals (NASDAQ:ANIP) reported positive six-month topline results from the Phase 4 SYNCHRONICITY trial evaluating fluocinolone acetonide intravitreal implant 0.18 mg in 108 patients with chronic non-infectious uveitis affecting the posterior segment.
Brightstar Lottery (NYSE:BRSL) announced that its subsidiary Brightstar Global Solutions received a seven-year contract extension to continue as the primary technology supplier for Washington’s Lottery through June 30, 2036.
Lazard (NYSE:LAZ) reported preliminary assets under management of approximately $284.7 billion as of June 30, 2026, reflecting market gains, currency movements and the acquisition of a controlling interest in Elaia Partners.
GSK (NYSE:GSK) reported positive interim results from the Phase II AZUR-1 trial of Jemperli (dostarlimab) in patients with stage II/III mismatch repair deficient or microsatellite instability-high locally advanced rectal cancer, with the study meeting its primary objective.
Meta Platforms (NASDAQ:META) announced that its data center in Richland Parish, Louisiana will expand to 5 gigawatts of computing capacity as the company increases infrastructure supporting its artificial intelligence development.
Emera (NYSE:EMA) declared quarterly dividends on its common shares and First Preferred Shares, including a payment of $0.7325 per common share scheduled for August 17, 2026.
Northern Oil and Gas (NYSE:NOG) reported second-quarter business updates, including estimated derivative gains of $155 million to $160 million, share repurchases of 2.95 million shares and an expanded share repurchase authorization of approximately US$243 million.
Incyte (NASDAQ:INCY) reported complete Phase 1/2 safety and efficacy data from 16 patients treated with latarcibart, an investigational Protein S-targeting antibody being developed for von Willebrand disease (VWD).
-1-640x359.webp&w=3840&q=75)
